Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: A double-blind, placebo-controlled, randomized trial

被引：21

作者：

Hoffman D.J. ^{[1
]}

Gerdes J.S. ^{[2
,3
]}

Abbasi S. ^{[2
]}

机构：

[1] Department of Neonatology, Reading Hospital Medical Center, West Reading, PA

[2] Section on Newborn Pediatrics, Pennsylvania Hospital, Univ. of Pennsylvania Sch. of Med., Philadelphia, PA

[3] University of Pennsylvania, School of Medicine, Philadelphia, PA 19107

来源：

Journal of Perinatology | 2000年 / 20卷 / 1期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/sj.jp.7200307

中图分类号：

学科分类号：

摘要：

OBJECTIVE: To study the effect of spironolactone on dietary electrolyte supplementation, pulmonary function, and electrolyte balance in premature infants with chronic lung disease. STUDY DESIGN A double-blind, randomized, and placebo-controlled trial was designed to study two groups of low birth weight infants with chronic lung disease at Pennsylvania Hospital. The placebo group received chlorothiazide and a placebo, and the spironolactone group received chlorothiazide and spironolactone during the 2-week study period. A two-tailed t-test was used to determine equivalence between the two groups. RESULTS Pulmonary compliance, resistance and tidal volume, serum sodium and potassium, and FIO2, were not statistically different between the two groups. The need for sodium and/or potassium chloride did not differ between the two groups, nor did the quantity of each salt CONCLUSION The addition of spironolactone did not reduce the requirement for supplemental electrolytes, nor did it improve pulmonary mechanics or electrolyte balance.

引用

页码：41 / 45

页数：4

共 23 条

[1]

Bancalari E., Neonatal chronic lung disease, Neonatal-Perinatal Medicine. Diseases of the Fetus and Infant, pp. 1074-1089, (1997)

[2]

Bhutani V.K., Abbasi S., Long-term pulmonary consequences in survivors with bronchopulmonary dysplasia, Clin Perinatol, 19, pp. 649-671, (1992)

[3]

Kao L.C., Warburton D., Cheng M.H., Cedeno C., Platzker A.C.G., Keens T.G., Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: Results of a double-blind crossover sequential trial, Pediatrics, 74, pp. 37-44, (1984)

[4]

Engelhardt B., Blalock W.A., Donlevy S., Rush M., Hazinski T.A., Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia, J Pediatr, 114, pp. 619-624, (1989)

[5]

Loggie J.M.H., Kleinman L.I., Van Maanen E.F., Renal function and diuretic therapy in infants and children. Part II, J Pediatr, 86, pp. 657-669, (1975)

[6]

Spitzer A., The role of the kidney in sodium homeostasis during maturation, Kidney Int, 21, pp. 539-545, (1982)

[7]

Ross B.S., Pollak A., Oh W., The pharmacologic effects of furosemide therapy in the low-birth-weight infant, J Pediatr, 92, pp. 149-152, (1978)

[8]

Mirochnick M.H., Miceli J.J., Kramer P.A., Chapron D.J., Raye J.R., Furosemide phar-macokinetics in very low birth weight infants, J Pediatr, 112, pp. 653-657, (1988)

[9]

Kao L.C., Warburton D., Sargent C.W., Platzker A.C.G., Keens T.G., Furosemide acutely decreases airway resistance in chronic bronchopulmonary dysplasia, J Pediatr, 103, pp. 624-629, (1983)

[10]

Engelhardt B., Elliott S., Hazinski T.A., Short and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia, J Pediatr, 109, pp. 1034-1039, (1986)

← 1 2 3 →